Drug development

#Biotechnology #DNA #Drug development #Drug discovery

Pioneering DNA-encoded chemical library technology

As an expert in DNA-encoded chemical library (DEL) technology, X-Chem has set up a free-to-register, interactive virtual booth to display how it efficiently unlocks possibilities in small molecule drug discovery and development. The booth includes information about X-Chem, a video library, brochures and insert sheets on mechanical chemistry,… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#Cancer research #Covid-19 #Drug development #Drug discovery #Drug repurposing #Research

How this chemotherapy cancer drug can be used to fight Covid-19

Mount Sinai researchers have found that widely available and inexpensive drug targeting inflammatory genes have reduced morbidity and mortality in mice infected with SARS-CoV-2. Following its publication in Cell, and reporting by DDW, Megan Thomas spoke to Dr Ivan Marazzi, co-author of the study and associate professor in the Microbiology… Read More

#Editor's Choice #Exclusive Content #News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Research

Academic investigates role of green tea compounds in Covid-19 drugs

University academic Dr Suresh Mohankumar has carried out research with colleagues in India during his time at JSS College of Pharmacy, JSS Academy of Higher Education and Research in Ooty prior to taking up his current role at Swansea University Medical School. Findings suggest that one of the compounds in… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Tumour biology

First patient dosed with Gadeta’s gamma delta TCR cell therapy

Gadeta, a clinical-stage company developing gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, has announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer. The multicentre Phase I/II study in collaboration with the Dana-Farber Cancer Institute,… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug delivery #Drug development #Pharma #Pharmaceuticals

Half of pharma believes AI can help bring new drugs to market faster

New research reveals that 50% of European and US pharmaceutical manufacturing companies know artificial intelligence (AI) can help bring new drugs to market more rapidly and securely, but 96% face challenges with using it to derive value from their data. 49% of all executives surveyed say their company has no… Read More

#News

Cannabis plant
#Cannabinoid #Clinical trials #Drug development #Drug discovery

Agreement will speed up cannabinoid drug development

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug… Read More

#News

#Anti-virals #Covid-19 #Drug development

Large-scale drug analysis reveals potential new Covid-19 antivirals

Researchers at the Francis Crick Institute and University of Dundee have screened thousands of drug and chemical molecules and identified a range of potential antivirals that could be developed into new treatments for Covid-19 or in preparation for future coronavirus outbreaks. While Covid-19 vaccines are being rolled out, there are… Read More

#Editor's Choice #News #Trending News

#Drug development #Drug discovery #Immunobiology #Research

Stem cells use same method as plants and insects to protect against viruses

Researchers at the Francis Crick Institute have found a vital mechanism, previously thought to have disappeared as mammals evolved, that helps protect mammalian stem cells from RNA viruses such as SARS-CoV-2 and Zika virus. The scientists suggest this could one day be exploited in the development of new antiviral treatments. Read More

#News

#Biomarkers #Drug development #Drug discovery #Neuroscience #Novel therapeutics #Therapeutics

Biomarker company raises £2.6 million for neuroscience drugs

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Biologics / Biotechnology #Bioscience #Biotechnology #Drug delivery #Drug development #Drug discovery

Switzerland: punching above its weight as global biotech hub

Listen to this article on the DDW Podcast:   To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman spoke to Michael Altorfer (CEO of the Swiss Biotech Association), Jan Lucht (Head of Biotechnology, scienceindustries), Claude Joris (Secretary General, BioAlps), and Carole Delauney (Business Development Director… Read More

#Editor's Choice #Exclusive Content #Market Reports #News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Drug screening #High throughput screening

What will this NIGMS grant mean for combatting rare diseases?

Sinopia Biosciences has been awarded a grant from the National Institute of General Medical Sciences (NIGMS), as part of the National Institutes of Health, to further develop and validate their proprietary metabolomics-based high-throughput screening (HTS) platform with an initial focus on rare diseases. To date, Sinopia has received nearly $8… Read More

#News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News

#Clinical trials #Drug development #Drug discovery #Research #Sclerosis

Gesynta Pharma announces significant progress across new drug candidate

Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More

#News